Two Vall d'Hebron projects receive the 2024 Gilead Biomedical Research Grants

The awarded projects will study the immune response to HIV and the VIGex tool as a biomarker for immunotherapy response.

18/10/2024

Vall d'Hebron has been awarded two of the prestigious Gilead Biomedical Research Grants in its 10th edition, which recognize excellent projects in HIV, COVID-19, Viral Hepatitis C and Delta, Invasive Fungal Infections, B-Cell Lymphomas, and Medical Oncology. The pharmaceutical company Gilead Sciences, in collaboration with the Carlos III Health Institute (ISCIII), held the awards ceremony for the 10th edition of the Gilead Biomedical Research Grants at the Teatro Real in Madrid.

The awarded projects are led by Dr. Meritxell Genesca Ferrer from Vall d'Hebron Research Institute (VHIR) and Dr. Alberto Hernando Calvo from Vall d'Hebron Institute of Oncology (VHIO).

The innate immune response to HIV infection study

Dr. Meritxell Genesca Ferrer, principal investigator of the Infectious Diseases Research Group at VHIR, received a grant to study the initial innate immune response to HIV infection in the female genital mucosa. This project aims to better understand the mechanisms involved in the early stages of HIV infection, especially how mucosal immunity is affected by exposure to the virus. Using human cervical explant models, her team will investigate the interaction between myeloid cells and unconventional T cells to identify potential pathways for infection prevention.

Validation of the VIGex tool as a biomarker for immunotherapy response

Dr. Alberto Hernando Calvo, medical oncologist at the Molecular Cancer Therapy Unit (UITM-CaixaResearch) at VHIO, was awarded another grant to validate VIGex, a tool developed to classify tumours based on their immune response. This biomarker will help identify which patients are more likely to respond to immunotherapy in clinical trials. The VIGex tool is based on the gene expression of 12 key genes and is an innovation driven by VHIO and the Princess Margaret Cancer Center in Toronto.

Gilead Grants: boosting Spanish biomedical research

The Gilead Biomedical Research Grants, in their 10th edition, selected 19 excellent projects with a total investment of one million euros. These grants are a benchmark in the field of research, driving scientific innovation in collaboration with the Carlos III Health Institute and other entities.
This recognition reaffirms Vall d'Hebron's commitment to cutting-edge biomedical research, aiming to provide solutions to the major medical challenges of our time.

Share it:

Notícies relacionades

Subscribe to our newsletters and be a part of Campus Life

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”.
Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health).
Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information.
Legal basis: Consent of the data subject.
Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen.
Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time.
Source: The data subject.
Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.